Hello Share Spillers. A company with the rather clumsy name of Cambridge Cognition Holdings (COG) appears worth a look. It’s a niche medical outfit that assists in organising clinical trials for drugs and treatments. Since Covid, there’s a sharper focus on the medical sector and more money being spent on it.
Hello Share Scrapers. It’s my often-voiced opinion that many companies in the medical sphere are worth a peek in these dangerous days. And that’s because Covid makes the world more aware of the value of good health. My latest commendation in this blazing field is a company that performs the essential service of helping to test new drugs.
Having filed patents and announced the start of the technology programme last year, Cambridge Cognition (COG) has now announced its “first voice-based cognitive assessments are available for use in its core pharmaceutical and biotechnology clinical trial channels”…
The theme of Monday's UK Investor City Show evening was disruptive technologies. That is certainly something Cambridge Cognition (COG) is working on. Nigel Wray is a big shareholders and has increased his stake of late. Watch the video to see why.
